Elan announced a series of transactions designed to transform the... 
Vortioxetine clinical phase III data show significant improvement in... 
XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen... 
Special Reports
Pharmalot
In what is apparently an unusual move, the US Department of Agriculture earlier this year fined Bristol-Myers Squibb...
After last year marked a notable drop in the value of pharmaceutical thefts, recent data indicates that those Soprano...
1
If there is a take-away message from the $8.5 billion deal in which Actavis is going to buy Warner-Chilcott, it would...
Our experts are on hand to offer industry-specific advice.
Business
- Relmada Therapeutics Gears Up To Become A Publicly Traded Company
- Community Oncology Organizations, Clinics and Patients Support the Bipartisan 'Preserve Community Cancer Care Act'
- BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute
Marketing & Advertising
- Relmada Therapeutics Gears Up To Become A Publicly Traded Company
- Community Oncology Organizations, Clinics and Patients Support the Bipartisan 'Preserve Community Cancer Care Act'
- BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute
Therapeutics
- Relmada Therapeutics Gears Up To Become A Publicly Traded Company
- Community Oncology Organizations, Clinics and Patients Support the Bipartisan 'Preserve Community Cancer Care Act'
- BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute
R&D
- Relmada Therapeutics Gears Up To Become A Publicly Traded Company
- Community Oncology Organizations, Clinics and Patients Support the Bipartisan 'Preserve Community Cancer Care Act'
- BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute